ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Illumina, Inc." (ILMN) Report Updated: May 04, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Illumina, Inc." (ILMN)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Life Sciences Tools & Services
Competitors:

Stock Analysis

Rating: Monthly View

A
B
C
D
F
May June July August September October November December January February March April

Rating: Weekly View

This Week: D down no change
Last Week: D same downgrade
Two Weeks Ago: C up no change
service keys

"Illumina, Inc."© quotemedia

Company Profile

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms consist of HiScan and iScan systems, as well as NextSeq 550 system that are array scanners for DNA and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis. It also offers various library preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping, noninvasive prenatal test, and whole-genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. It has a collaboration agreement with Merck Serono to develop a sequencing-based oncology diagnostic; Burning Rock to develop molecular diagnostics for oncology; and Memorial Sloan Kettering Cancer Center to develop of strategies to diagnose and monitor cancer, and establish ctDNA as an important marker in the study and eventual treatment of cancer. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.